V1a Receptor Antagonists for Blood-Brain Barrier Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current V1a receptor modulators, particularly antagonists, face challenges in effectively treating conditions like dysmenorrhea, sexual dysfunction, hypertension, and neuropsychological disorders due to limited penetration through the blood-brain barrier and potential side effects from off-target interactions.
Innovation Solution
Development of specific 4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulene compounds that act as V1a receptor antagonists, designed to improve penetration across the blood-brain barrier and minimize off-target effects by selective inhibition of the V1a receptor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current V1a receptor modulators are used, then therapeutic effects are achieved, but penetration through the blood-brain barrier is limited
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of V1a receptor modulators, specifically varying substituents at positions R1-R6 to optimize the balance between therapeutic efficacy and blood-brain barrier penetration. Different substituent patterns (halogens, alkyl groups, aryl groups, heteroaryl groups) are explored to achieve the desired pharmacokinetic profile.
2Reliability
If current V1a receptor modulators are used, then therapeutic effects are achieved, but off-target interactions cause side effects
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at particular positions on the molecular scaffold. For example, specific combinations of substituents at R3-R4 positions or R5-R6 positions are designed to enhance selectivity for the V1a receptor while minimizing interactions with other receptor subtypes, thereby reducing off-target effects.
3Object-generated harmful factors
If selective V1a receptor inhibition is achieved, then off-target side effects are reduced, but penetration through the blood-brain barrier remains limited
Solution Approach 1:
The patent applies dynamics by creating a series of analogs with varying degrees of lipophilicity and molecular size through different substituent combinations. This allows dynamic optimization where compounds can be tuned to achieve the right balance between selective V1a receptor binding and adequate blood-brain barrier penetration for central nervous system indications.
Data Source
AI summary
The present invention provides 4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.